GlassScriptPhysician profile
Sunil Rathore
NPI 1427435635
$1,009.76
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2021: $14.00 · 2022: $12.21 · 2023: $93.17 · 2024: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $485.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $484.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $339.60 | 2019-2023 | Ultomiris |
| Actelion Pharmaceuticals US, INC. | $175.86 | 2024 | Opsumit, Uptravi |
| Boston Scientific Corporation | $144.35 | 2024 | Watchman Flx |
| Portola Pharmaceuticals, LLC | $72.39 | 2019 | |
| Eisai INC. | $64.38 | 2019-2024 | |
| Lilly USA, LLC | $35.19 | 2023 | Emgality, Reyvow, Amyvid |
| Mallinckrodt Hospital Products INC. | $27.22 | 2024 | Acthar |
| Astrazeneca Pharmaceuticals LP | $26.21 | 2021-2022 | |
| Averitas Pharma INC. | $24.53 | 2023 | Qutenza |
| Genzyme Corporation | $20.78 | 2024 | |
| Novartis Pharmaceuticals Corporation | $17.52 | 2019 | |
| Amgen INC. | $17.18 | 2019 | |
| Csl Behring | $17.13 | 2019 | |
| Avanir Pharmaceuticals, INC. | $16.28 | 2019 | |
| Adamas Pharmaceuticals, INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Rathore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.